BR112022003143A2 - Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i. - Google Patents
Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i.Info
- Publication number
- BR112022003143A2 BR112022003143A2 BR112022003143A BR112022003143A BR112022003143A2 BR 112022003143 A2 BR112022003143 A2 BR 112022003143A2 BR 112022003143 A BR112022003143 A BR 112022003143A BR 112022003143 A BR112022003143 A BR 112022003143A BR 112022003143 A2 BR112022003143 A2 BR 112022003143A2
- Authority
- BR
- Brazil
- Prior art keywords
- binds
- lgr5
- egfr
- antibody
- topoisomerase inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i. a invenção descreve anticorpos ou partes funcionais, derivados e/ou análogos dos mesmos que compreendem um domínio variável que se liga a uma parte extracelular do egfr e um domínio variável que se liga a uma parte extracelular do lgr5 para uso no tratamento de câncer, sendo que o anticorpo ou parte funcional, derivado e/ou análogo do mesmo é administrado com um inibidor de topoisomerase i.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19192327 | 2019-08-19 | ||
PCT/NL2020/050517 WO2021034194A2 (en) | 2019-08-19 | 2020-08-19 | Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor. |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022003143A2 true BR112022003143A2 (pt) | 2022-05-17 |
Family
ID=67659296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022003143A BR112022003143A2 (pt) | 2019-08-19 | 2020-08-19 | Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230084382A1 (pt) |
EP (1) | EP4017879A2 (pt) |
JP (2) | JP2022545457A (pt) |
KR (1) | KR20220048015A (pt) |
CN (2) | CN116333154A (pt) |
AU (1) | AU2020331879A1 (pt) |
BR (1) | BR112022003143A2 (pt) |
CA (1) | CA3151641A1 (pt) |
IL (1) | IL290247A (pt) |
MX (1) | MX2022002096A (pt) |
WO (1) | WO2021034194A2 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240207457A1 (en) * | 2021-05-11 | 2024-06-27 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Cancer-specific polypeptide and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
ATE322265T1 (de) * | 2000-05-15 | 2006-04-15 | Celgene Corp | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält |
DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
HUE057994T2 (hu) | 2008-06-27 | 2022-06-28 | Merus Nv | Antitesttermelõ, transzgenikus, egérfélékhez tartozó állat |
CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
CN108026174B (zh) | 2015-07-10 | 2023-02-17 | 美勒斯公司 | 人cd3结合抗体 |
CN108602888B (zh) * | 2015-10-23 | 2022-10-04 | 美勒斯公司 | 抑制癌症生长的结合分子 |
AU2017239038B2 (en) * | 2016-03-22 | 2024-06-27 | Bionomics Inc | Administration of an anti-LGR5 monoclonal antibody |
-
2020
- 2020-08-19 EP EP20758359.2A patent/EP4017879A2/en active Pending
- 2020-08-19 US US17/632,181 patent/US20230084382A1/en active Pending
- 2020-08-19 MX MX2022002096A patent/MX2022002096A/es unknown
- 2020-08-19 KR KR1020227008659A patent/KR20220048015A/ko unknown
- 2020-08-19 BR BR112022003143A patent/BR112022003143A2/pt unknown
- 2020-08-19 CN CN202210968392.5A patent/CN116333154A/zh active Pending
- 2020-08-19 CA CA3151641A patent/CA3151641A1/en active Pending
- 2020-08-19 JP JP2022511055A patent/JP2022545457A/ja active Pending
- 2020-08-19 WO PCT/NL2020/050517 patent/WO2021034194A2/en active Application Filing
- 2020-08-19 AU AU2020331879A patent/AU2020331879A1/en active Pending
- 2020-08-19 CN CN202080058714.1A patent/CN114555115A/zh active Pending
-
2022
- 2022-01-30 IL IL290247A patent/IL290247A/en unknown
-
2024
- 2024-03-19 JP JP2024043606A patent/JP2024075676A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL290247A (en) | 2022-03-01 |
EP4017879A2 (en) | 2022-06-29 |
JP2022545457A (ja) | 2022-10-27 |
CN114555115A (zh) | 2022-05-27 |
MX2022002096A (es) | 2022-03-17 |
CA3151641A1 (en) | 2021-02-25 |
AU2020331879A1 (en) | 2022-02-24 |
WO2021034194A2 (en) | 2021-02-25 |
JP2024075676A (ja) | 2024-06-04 |
CN116333154A (zh) | 2023-06-27 |
KR20220048015A (ko) | 2022-04-19 |
US20230084382A1 (en) | 2023-03-16 |
WO2021034194A3 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
BR112018014759A2 (pt) | derivados de maitansinoide, conjugados dos mesmos e métodos de uso | |
BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
BR112022014189A2 (pt) | Conjugado de anticorpo anti-trop-2 análogo de exatecano e uso médico do mesmo | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
BR112016010271A2 (pt) | Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação | |
BR112021023024A2 (pt) | Anticorpo contra claudina 18a2 e uso do mesmo | |
CL2019003430A1 (es) | Tratamiento conjunto antineoplásico. | |
BR112016008010A2 (pt) | uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose | |
BR112019008417A2 (pt) | compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y | |
BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina | |
BR112017027246A2 (pt) | marcador de indução de degradação de proteína e uso do mesmo | |
BR112022003282A2 (pt) | Glicovariantes de igm | |
BR112018008900A2 (pt) | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas | |
BR112022003143A2 (pt) | Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i. | |
BR112015016817A8 (pt) | métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica | |
BR112019003712A2 (pt) | composições marcadoras, e métodos para produção e uso das mesmas | |
BR112022004831A2 (pt) | Anticorpos que se ligam a vista em ph ácido | |
BR112019020412A2 (pt) | composições e métodos para detectar câncer de pulmão | |
CL2022002833A1 (es) | Anticuerpos anti-flt3 y composiciones | |
CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
BR112017027617A2 (pt) | tala nasal | |
CO2021005579A2 (es) | Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3 |